JP2024161509A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024161509A5 JP2024161509A5 JP2024136804A JP2024136804A JP2024161509A5 JP 2024161509 A5 JP2024161509 A5 JP 2024161509A5 JP 2024136804 A JP2024136804 A JP 2024136804A JP 2024136804 A JP2024136804 A JP 2024136804A JP 2024161509 A5 JP2024161509 A5 JP 2024161509A5
- Authority
- JP
- Japan
- Prior art keywords
- multivalent antibody
- linker comprises
- hinge sequence
- antibody according
- multivalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650467P | 2018-03-30 | 2018-03-30 | |
| US62/650,467 | 2018-03-30 | ||
| PCT/NL2019/050199 WO2019190327A2 (en) | 2018-03-30 | 2019-03-29 | Multivalent antibody |
| JP2021502692A JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Division JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024161509A JP2024161509A (ja) | 2024-11-19 |
| JP2024161509A5 true JP2024161509A5 (enExample) | 2025-04-02 |
Family
ID=66349617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Active JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
| JP2024136804A Pending JP2024161509A (ja) | 2018-03-30 | 2024-08-16 | 多価抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502692A Active JP7603578B2 (ja) | 2018-03-30 | 2019-03-29 | 多価抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11952424B2 (enExample) |
| EP (1) | EP3774885A2 (enExample) |
| JP (2) | JP7603578B2 (enExample) |
| KR (1) | KR20200139189A (enExample) |
| CN (1) | CN111936514A (enExample) |
| AR (1) | AR115320A1 (enExample) |
| AU (2) | AU2019243665B2 (enExample) |
| BR (1) | BR112020019795A2 (enExample) |
| CA (1) | CA3094318A1 (enExample) |
| EA (1) | EA202091871A1 (enExample) |
| IL (1) | IL277672A (enExample) |
| MA (1) | MA52212A (enExample) |
| MX (1) | MX2020010267A (enExample) |
| NZ (1) | NZ767923A (enExample) |
| PH (1) | PH12020551504A1 (enExample) |
| SG (1) | SG11202009036YA (enExample) |
| TW (1) | TW202003569A (enExample) |
| WO (1) | WO2019190327A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52212A (fr) | 2018-03-30 | 2021-02-17 | Merus Nv | Anticorps multivalent |
| JP7443376B2 (ja) | 2018-12-31 | 2024-03-05 | メルス ナムローゼ フェンノートシャップ | 混合結合ドメイン |
| CN113439089A (zh) | 2018-12-31 | 2021-09-24 | 美勒斯公司 | 截短的多价多元体 |
| CN114605546A (zh) * | 2019-03-29 | 2022-06-10 | 美勒斯公司 | Cd3结合分子 |
| TW202546002A (zh) * | 2019-03-29 | 2025-12-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
| CA3139402A1 (en) | 2019-05-09 | 2020-11-12 | Merus N.V. | Variant domains for multimerizing proteins and separation thereof |
| AU2020412201B2 (en) | 2019-12-24 | 2026-02-12 | Merus B.V. | TGF-beta-RII binding proteins |
| US20230210988A1 (en) * | 2020-01-29 | 2023-07-06 | Merus N.V. | Means and method for modulating immune cell engaging effects |
| US20230151115A1 (en) * | 2020-03-31 | 2023-05-18 | University Public Corporation Osaka | Multispecific antibody and method for producing same |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226984A1 (zh) | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| CA3175227A1 (en) | 2020-05-21 | 2021-11-25 | Cornelis De Kruif | Methods and means for the production of ig-like molecules |
| EP4244382A1 (en) * | 2020-11-11 | 2023-09-20 | Nautilus Subsidiary, Inc. | Affinity reagents having enhanced binding and detection characteristics |
| CN115536749A (zh) * | 2021-06-29 | 2022-12-30 | 三生国健药业（上海）股份有限公司 | 三特异性抗体、其制备方法和用途 |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| AU2023228391A1 (en) * | 2022-03-03 | 2024-09-19 | Pfizer Inc. | Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof |
| US20230383012A1 (en) * | 2022-04-13 | 2023-11-30 | Xencor, Inc. | Antibodies that bind pd-l1, pd-l2, and/or cd28 |
| CN120641444A (zh) | 2022-12-27 | 2025-09-12 | 美勒斯公司 | 产生双重特异性蛋白的方法 |
| WO2024144400A1 (en) * | 2022-12-30 | 2024-07-04 | Merus N.V. | Promiscuous cd3 binding molecules |
| CN116813744B (zh) * | 2023-02-23 | 2024-02-23 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
| WO2024206568A2 (en) * | 2023-03-31 | 2024-10-03 | Ibio, Inc. | Anti-cd3 antibodies |
| WO2025230409A1 (en) | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2025230410A1 (en) | 2024-04-30 | 2025-11-06 | Merus N.V. | Multispecific antibody-drug conjugates |
| WO2026013015A1 (en) * | 2024-07-09 | 2026-01-15 | Merus N.V. | Multispecific binding moieties comprising calr and cd3 binding domains |
| WO2026018064A1 (en) | 2024-07-16 | 2026-01-22 | Merus N.V. | Multispecific multi-drug antibody-drug conjugates |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| ES2637801T3 (es) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
| AU2001270609A1 (en) * | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| ATE545703T1 (de) * | 2000-07-25 | 2012-03-15 | Immunomedics Inc | Multivalentes zielbindendes protein |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PT3456190T (pt) | 2008-06-27 | 2022-02-15 | Merus Nv | Animal murino transgénico produtor de anticorpo |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| AU2010249470B2 (en) | 2009-05-20 | 2015-06-25 | Novimmune S.A. | Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants |
| EP2435473B1 (en) * | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| EP2513312B1 (en) | 2009-12-17 | 2015-03-18 | NovImmune SA | Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants |
| GB201000467D0 (en) * | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| US20120195900A1 (en) | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| MX2014002289A (es) * | 2011-08-26 | 2015-03-20 | Merrimack Pharmaceuticals Inc | Anticuerpos fc especificos en tandem. |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| DK2838917T3 (da) | 2012-04-20 | 2019-08-26 | Merus Nv | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| CN104736168B (zh) | 2012-05-31 | 2018-09-21 | 索伦托治疗有限公司 | 与pd-l1结合的抗原结合蛋白 |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| HRP20181717T1 (hr) | 2012-09-27 | 2018-12-28 | Merus N.V. | Bispecifična igg protutijela kao aktivatori t stanice |
| ES2667420T3 (es) | 2013-02-05 | 2018-05-10 | Engmab Sàrl | Anticuerpos biespecíficos contra cd3epsilon y bcma |
| WO2014131711A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| NZ720353A (en) * | 2013-12-30 | 2019-12-20 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
| HRP20250041T1 (hr) | 2014-02-28 | 2025-03-14 | Merus N.V. | Antitijelo koje veže erbb-2 i erbb-3 |
| ES2816624T3 (es) | 2014-02-28 | 2021-04-05 | Merus Nv | Anticuerpos que se unen a EGFR y ERBB3 |
| TWI742423B (zh) | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| US20170306044A1 (en) | 2014-10-09 | 2017-10-26 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
| AU2015329965A1 (en) | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
| AU2016233495B2 (en) | 2015-03-13 | 2022-02-24 | Cytomx Therapeutics, Inc | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
| ES2693596T3 (es) * | 2015-07-10 | 2018-12-12 | Merus N.V. | Anticuerpo que se une a CD3 humano |
| EP3670535A1 (en) | 2015-08-03 | 2020-06-24 | EngMab Sàrl | Monoclonal antibodies against bcma |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| KR20250157457A (ko) * | 2015-10-23 | 2025-11-04 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
| PT3998285T (pt) | 2016-03-25 | 2025-04-14 | Biomunex Pharmaceuticals | Moléculas de ligação a cd38 e pd-l1 |
| PE20181952A1 (es) * | 2016-04-27 | 2018-12-17 | Pfizer | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos |
| RU2018141777A (ru) | 2016-04-28 | 2020-05-28 | Биомюнё Фармасьютикалз | Биспецифичные антитела, нацеленные на egfr и her2 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| CN109983033B (zh) | 2016-09-23 | 2023-10-31 | 美勒斯公司 | 调节细胞表达的生物活性的结合分子 |
| KR102617264B1 (ko) | 2016-10-19 | 2023-12-29 | 인벤라 인코포레이티드 | 항체 구조물 |
| US11124577B2 (en) | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| WO2018182422A1 (en) * | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
| EP3600411A1 (en) * | 2017-03-31 | 2020-02-05 | Merus N.V. | Antibodies for the treatment of erbb-2/erbb-3 positive tumors |
| TW202542197A (zh) * | 2017-07-06 | 2025-11-01 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
| IL271832B2 (en) * | 2017-07-06 | 2025-07-01 | Merus Nv | Bispecific anti pd1-anti tim3 antibodies and uses thereof |
| EA202090003A1 (ru) * | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка |
| PL3665198T3 (pl) * | 2017-08-09 | 2025-06-09 | Merus N.V. | Przeciwciała wiążące egfr i cmet |
| US20200384084A1 (en) * | 2017-12-01 | 2020-12-10 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
| MA52212A (fr) | 2018-03-30 | 2021-02-17 | Merus Nv | Anticorps multivalent |
| JP7443376B2 (ja) * | 2018-12-31 | 2024-03-05 | メルス ナムローゼ フェンノートシャップ | 混合結合ドメイン |
| CA3139402A1 (en) * | 2019-05-09 | 2020-11-12 | Merus N.V. | Variant domains for multimerizing proteins and separation thereof |
| CN114761037A (zh) * | 2019-11-26 | 2022-07-15 | 诺华股份有限公司 | 结合bcma和cd19的嵌合抗原受体及其用途 |
| US20230210988A1 (en) * | 2020-01-29 | 2023-07-06 | Merus N.V. | Means and method for modulating immune cell engaging effects |
-
2019
- 2019-03-29 MA MA052212A patent/MA52212A/fr unknown
- 2019-03-29 JP JP2021502692A patent/JP7603578B2/ja active Active
- 2019-03-29 KR KR1020207030642A patent/KR20200139189A/ko not_active Ceased
- 2019-03-29 NZ NZ767923A patent/NZ767923A/en unknown
- 2019-03-29 EP EP19721163.4A patent/EP3774885A2/en active Pending
- 2019-03-29 WO PCT/NL2019/050199 patent/WO2019190327A2/en not_active Ceased
- 2019-03-29 AU AU2019243665A patent/AU2019243665B2/en active Active
- 2019-03-29 US US16/370,346 patent/US11952424B2/en active Active
- 2019-03-29 MX MX2020010267A patent/MX2020010267A/es unknown
- 2019-03-29 CA CA3094318A patent/CA3094318A1/en active Pending
- 2019-03-29 SG SG11202009036YA patent/SG11202009036YA/en unknown
- 2019-03-29 TW TW108111354A patent/TW202003569A/zh unknown
- 2019-03-29 BR BR112020019795-5A patent/BR112020019795A2/pt unknown
- 2019-03-29 AR ARP190100836A patent/AR115320A1/es unknown
- 2019-03-29 CN CN201980023259.9A patent/CN111936514A/zh active Pending
- 2019-03-29 EA EA202091871A patent/EA202091871A1/ru unknown
-
2020
- 2020-09-16 PH PH12020551504A patent/PH12020551504A1/en unknown
- 2020-09-29 IL IL277672A patent/IL277672A/en unknown
-
2023
- 2023-09-01 AU AU2023222983A patent/AU2023222983A1/en active Pending
-
2024
- 2024-02-13 US US18/440,582 patent/US20240360217A1/en active Pending
- 2024-02-13 US US18/440,607 patent/US20240352127A1/en active Pending
- 2024-08-16 JP JP2024136804A patent/JP2024161509A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024161509A5 (enExample) | ||
| JP6753945B2 (ja) | 抗人ｐｄ−ｌ１人源化単クローン抗体及び応用 | |
| Wu et al. | Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules | |
| Schuster | Bispecific antibodies for the treatment of lymphomas: Promises and challenges | |
| TWI676681B (zh) | 具抗原專一性的t細胞及其用途 | |
| CN113677359A (zh) | Cd25抗体 | |
| CN109219619A (zh) | 抗lag-3抗体 | |
| AU680685B2 (en) | Retargeting antibodies | |
| JPH03500005A (ja) | 組換えｄｎａタンパクの製造方法 | |
| JP2006515503A5 (enExample) | ||
| KR960704575A (ko) | 항원-특이적 t 세포의 내성을 유도하는 방법(methods for inducing antigen-specific tcell tolerance) | |
| JP2021530207A (ja) | 二重特異性抗体及びその使用 | |
| JP2020007318A5 (enExample) | ||
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| AU2022273136A9 (en) | Binding molecule against dll3 and use thereof | |
| JP2024514109A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JPH01501201A (ja) | 抗体 | |
| Silverstein | Labeled antigens and antibodies: the evolution of magic markers and magic bullets | |
| Sandeep et al. | Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics | |
| Shinde et al. | Polyvalency: an emerging trend in the development of clinical antibodies | |
| TWI685504B (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
| Winter | Antibody engineering | |
| JP2010529950A5 (enExample) | ||
| CN110577598A (zh) | 抗sFcεRIα单克隆抗体及其应用 | |
| CN118702814A (zh) | 一种抗ngf单克隆抗体及其应用 |